Search
forLearn
5 / 36 resultslearn Unknown herbal complex (freshly cosmetics)
learn Vitis vinifera
learn Hair Fibers
cosmetic product that temporarily makes hair appear thicker
learn Melatonin
hormone commonly taken for sleep aid has some topical benefits for hair
Research
5 / 1000+ resultsresearch Common Contact Allergens Implicated In Frontal Fibrosing Alopecia Found In Over-The-Counter Hair Growth Serums And Solutions
Over-the-counter hair growth products may cause frontal fibrosing alopecia due to allergens.
research Cosmos Caudatus Kunth Leaf Extract Herbal Nanosuspension Formulations, Characterization, and Cytotoxicity Approach Against MCF-7 Breast Cancer Cells
Kenikir leaf extract nanosuspension may help inhibit breast cancer cell growth.
research Modulation of AR-FGF-2-TGF Beta Axis by Cosmos Caudatus Suppresses Prostatic Epithelial Proliferation in a BPH Rat Model: A Comparative Study with Finasteride
Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
research Classification of the Types of Androgenetic Alopecia (Common Baldness) Occurring in the Female Sex
Common baldness, also known as Androgenetic Alopecia, is caused by a combination of genetic factors and hormones called androgens.
research Common Variants in the Trichohyalin Gene Are Associated with Straight Hair in Europeans
Common variants in the Trichohyalin gene are linked to straight hair in Europeans.
Community Join
5 / 1000+ resultscommunity Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
community Cosmo Pharma Lists Breezula Phase 3 Trial on ClinicalTrials.gov
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
community Common hair-loss drug consistently associated with higher rates of psychiatric harm
Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.
community cosmeRNA finally now it's pyrilutamide turn
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.